As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

Med Ad News talked to Bill Dreitlein – Senior Director, Pipeline & Drug Surveillance at OptumRx – about some of the most promising new molecular entities in the industry pipeline and challenges the FDA has faced during the COVID-19 pandemic.

Todd Wills, Managing Director, Consulting Services at CAS, talked to Med Ad News about what COVID-19 has taught us about pharmaceutical R&D; insights and predictions on future drug approval trends; and other topics.

The promise of personalized medicine, with its potential for treatments tailored to individual patients’ genomic footprints to generate better outcomes, has long tantalized the life sciences industry. Now, advanced imaging analytics and the extraction of high dimensional data from medical images, called radiomics, is emerging as the other side of the personalization coin.

Kevin Jacob, Head of Imaging at Illingworth Research Group (a SYNEOS HEALTH company), touches upon the myriad potential applications of medical photography and explore key considerations for use of these highly technical imaging techniques in clinical trials. 

ExplORer Surgical CEO Jennifer Fried discusses the evolving need for AI and AR technology in the healthcare industry as a whole and the COVID-19 pandemic’s effects on the medical device industry.

FCB Health Network kicked off 2021 with prominent hires at several creative agencies. Additionally, in honor of World Cancer Day, the network announced “The Trial for #ClinicalEquality,” an initiative dedicated to achieving racial equity in clinical trials.

Dr. Christina Reimer was appointed chief medical officer at Stockholm-based Alligator Bioscience.

Biotechnology company Rinri Therapeutics made Dr. Terri Gaskell chief technology officer and a member of the executive team.

2019 was a good year for the pharma industry, even as questions on value kept coming; but 2020 brought a pandemic that raised an “all hands on deck” attitude as well as business challenges.